Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Jinxin Fertility (锦欣生殖) Placement -   A Familiar Name by Now and Don't Expect Extravagant Returns

Jinxin Fertility: Signs of Policy Tailwind and Valuation Dislocation

Jinxin Fertility 1H2021: A Clear Picture of the Long Term Potential

Jinxin Fertility: Long Term IVF Story Intact Despite Potential Post Results De-Rating

China: 3rd Child Policy and 3 Beneficiaries

Jinxin Fertility (锦欣生殖) Placement - Setting up for Acquisitions

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Jinxin Fertility Group  / Equity Capital Markets

<p>Jinxin Fertility announced the acquisition of 19.33% indirect economic interest in two Yunnan based hospitals in China and hosted an online NDR in its Wuhan Hospital last Saturday. In this note, we will provide an update on the acquisition and the NDR. We believe that Jinxin Fertility is a quality ARS-focused healthcare group with a wide moat and differentiated service. </p>

Jinxin Fertility announced the acquisition of 19.33% indirect economic interest in two Yunnan based hospitals in China and hosted an online NDR in its Wuhan Hospital last Saturday. In this note, we will provide an update on the acquisition and the NDR. We believe that Jinxin Fertility is a quality ARS-focused healthcare group with a wide moat and differentiated service. 

Jinxin Fertility: Takeaways from Wuhan NDR and Yunnan Acquisition